| Literature DB >> 29743389 |
Makiko Nakano1, Kazuyuki Omae1, Toru Takebayashi1, Shigeru Tanaka2, Shigeki Koda3.
Abstract
BACKGROUND: ortho-Toluidine (OT) was listed as a Group 1 carcinogen by the International Agency for Research on Cancer in 2012 based on epidemiological observations of workers co-exposed to OT and aromatic amines. From 2014 to 2017, several cases of bladder cancer (BCa) secondary to occupational exposure, primarily to OT, were detected in Japan.Entities:
Keywords: 2,4-xylidine; Aniline; Bladder cancer; Dermal absorption; ortho-toluidine
Mesh:
Substances:
Year: 2018 PMID: 29743389 PMCID: PMC6078838 DOI: 10.1539/joh.2017-0220-OA
Source DB: PubMed Journal: J Occup Health ISSN: 1341-9145 Impact factor: 2.708
Fig. 1.Flow diagram of the materials and procedures used by the workers
Surrogate exposure levels and urinary tract abnormalities in BCa cases.
| Case | 1 | 2 | 3* | 4* | 5 | 6 | 7* | 8 | 9* | 10 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases are ordered based on the surrogate level of OT exposure. The surrogate level of exposure to each aromatic amine was calculated as the total job-weight/month for each process for each job-year. Job-weight/month was allocated as follows: 0 (none), 1 (l―2 days per month), 5 (3―9 days per month), and 10 (more than 10 days per month). OT: | ||||||||||||
| Surrogate level of exposure | ||||||||||||
| OT | 440 | 395 | 380 | 370 | 310 | 258 | 215 | 160 | 105 | 100 | ||
| MX | 121 | 315 | 190 | 192 | 155 | 282 | 202 | 80 | 110 | - | ||
| AN | 256 | 122 | 237 | 175 | 142 | 470 | 155 | 107 | 115 | - | ||
| OA | - | - | - | - | - | 65 | - | - | 60 | 180 | ||
| OCA | - | - | - | 38 | - | - | - | - | 75 | - | ||
| PT | - | - | - | - | - | - | - | - | - | 195 | ||
| Smoking status | Pack-years | 32 | 36 | 0 | 33 | 15 | 39 | 29.3 | 10 | 45 | 0 | |
| Past histories of urinary tract diseases, signs or symptoms: Years before the BCa diagnosis: | ||||||||||||
| Cystitis | 5 | 11 | - | - | 21 | - | - | 11―2(5 times) | - | - | ||
| Interstitial cystitis | - | - | - | - | - | - | - | - | - | 2 | ||
| Gross hematuria | 0 | 0 | 1 | 1 | 12, 7, 2 | 0 | - | 2 | - | 0 | ||
| Microscopic hematuria | - | - | - | 22―1 | - | - | - | - | - | - | ||
| Incomplete emptying of the bladder | - | 11 | - | 1―0 | 21 | - | - | 2―0 | - | 2―0 | ||
| Dysuria | 12, 5 | 11 | 17―1 | 1―0 | 21 | - | - | - | - | 0 | ||
| Ureteral stones | - | 24# | - | 22 | - | - | - | - | - | - | ||
| Subjective symptom at BCa diagnosis | ||||||||||||
| Hematuria | + | + | + | + | + | + | - | - | - | + | ||
| Incomplete emptying of the bladder | - | - | - | - | - | - | - | + | - | + | ||
| Dysuria | - | - | + | - | - | - | - | - | - | + | ||